Financial Fitness Check: Examining 4D Molecular Therapeutics Inc (FDMT)’s Key Ratios

Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

In the latest session, 4D Molecular Therapeutics Inc (NASDAQ: FDMT) closed at $22.57 down -0.66% from its previous closing price of $22.72. In other words, the price has decreased by -$0.66 from its previous closing price. On the day, 0.68 million shares were traded. FDMT stock price reached its highest trading level at $22.875 during the session, while it also had its lowest trading level at $21.805.


For a deeper understanding of 4D Molecular Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 32.65 and its Current Ratio is at 32.65. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on April 15, 2024, initiated with a Overweight rating and assigned the stock a target price of $459.

On April 15, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $45.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 16 ’24 when Bizily Scott sold 1,750 shares for $25.45 per share. The transaction valued at 44,541 led to the insider holds 1,737 shares of the business.

Bizily Scott sold 1,750 shares of FDMT for $45,045 on Apr 16 ’24. The Chief Legal Officer now owns 1,737 shares after completing the transaction at $25.74 per share. On Apr 01 ’24, another insider, Bizily Scott, who serves as the Chief Legal Officer of the company, sold 8,153 shares for $31.78 each. As a result, the insider received 259,102 and left with 1,737 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FDMT now has a Market Capitalization of 1166945664 and an Enterprise Value of 655206016. For the stock, the TTM Price-to-Sale (P/S) ratio is 53.06 while its Price-to-Book (P/B) ratio in mrq is 1.92. Its current Enterprise Value per Revenue stands at 32.035 whereas that against EBITDA is -5.622.

Stock Price History:

Over the past 52 weeks, FDMT has reached a high of $36.25, while it has fallen to a 52-week low of $9.44. The 50-Day Moving Average of the stock is -12.79%, while the 200-Day Moving Average is calculated to be 11.15%.

Shares Statistics:

For the past three months, FDMT has traded an average of 581.25K shares per day and 623280 over the past ten days. A total of 51.70M shares are outstanding, with a floating share count of 43.45M. Insiders hold about 15.96% of the company’s shares, while institutions hold 97.35% stake in the company. Shares short for FDMT as of 1715731200 were 9646011 with a Short Ratio of 16.60, compared to 1713139200 on 9834818. Therefore, it implies a Short% of Shares Outstanding of 9646011 and a Short% of Float of 19.33.

Most Popular